HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hendeles, L. Articles by Carlson, L. Search for Related Content PubMed PubMed Citation Articles by Hendeles, L. Articles by Carlson, L. Social Bookmarking                         What's this?

LESLIE HENDELES, PHARM.D., is Professor, Pharmacy and Pediatrics, University of Florida (UF), Gainesville. RANDY C. HATTON, PHARM.D., FCCP, BCPS, is Co-Director, Drug Information and Pharmacy Resource Center, Shands Hospital at the University of Florida (SHUF), and Clinical Professor, College of Pharmacy, UF. TIMOTHY J. COONS, R.R.T., M.B.A., is Director, Cardiopulmonary Services, and LEAH CARLSON, R.R.T., is Clinical Coordinator, Respiratory Care Services, SHUF.

Address correspondence to Dr. Hendeles at the Health Science Center, University of Florida, Box 100486, Gainesville, FL 32610-0486 (hendeles{at}cop.ufl.edu).

Purpose. Evidence supporting the delivery of bronchodilators with a metered-dose inhaler and a valved holding chamber (MDI+VHC) in place of a small-volume nebulizer (SVN) is discussed, and the steps taken to accomplish such a conversion program at one institution are described. Summary. Double-blind, randomized studies in patients with acute exacerbations of asthma have demonstrated that higher doses of albuterol delivered by MDI+VHC (4–10 puffs per dose) are as effective as 2.5 mg of albuterol sulfate delivered by SVN. Three double-blind studies support the conclusion that the two methods are equivalent with respect to both efficacy and adverse effects in patients with chronic obstructive pulmonary disease. MDI+VHC offers practical advantages over SVN, including the capacity for home use by the patient, portability, less setup time, and no need for daily disinfection. Pharmacists and respiratory therapists obtained approval through the pharmacy and therapeutics committee for respiratory therapists to convert orders for bronchodilators delivered by SVN to administration by MDI+VHC. The conversion policy allows physicians to override it, but none have exercised this option. On intensive care units (ICUs), the policy resulted in a 53% increase in the use of MDI+VHC during the six-month period after it went into effect. Respiratory therapists have been less thorough in implementing the policy for non-ICU patients. Conclusion. Delivery of bronchodilators by MDI+VHC is as effective as delivery by SVN but offers several advantages. A policy to switch patients from SVN to MDI+VHC for bronchodilator administration met with limited success. Index terms: Administration; Albuterol sulfate; Asthma; Devices; Dosage; Hospitals; Inhalers; Lung diseases; Sympathomimetic agents; Toxicity

 

CiteULike    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				N. M Clark, C. Houle, M. R Partridge, H. L Leo, and J. Y Paton The puzzle of continued use of nebulized therapy by those with asthma Chronic Respiratory Disease, February 1, 2010; 7(1): 3 - 7. [PDF]